AgomAb Therapeutics NV (AGMB) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
REGENXBIO is the larger company by market cap ($534.0 million vs $454.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | RGNX |
|---|---|---|
| Share price | $9.22 | $8.09 |
| Market cap | $454.07M | $534.05M |
| 1-day change | +4.77% | +6.52% |
| YTD return | — | -43.82% |
| 1-year return | — | -33.80% |
| 5-year return | — | -77.50% |
| EPS (TTM) | $-2.08 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $16.19 |
| 52-week low | $7.97 | $5.46 |
| Distance from 52-week high | -48.26% | -50.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +308.57% | +191.47% |
| Average volume | 136.54K | 1.52M |
| Shares outstanding | 49.25M | 66.01M |
| Employees | 62 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
AGMB vs RGNX FAQ
Which is bigger, AgomAb Therapeutics NV or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $534.05M compared with $454.07M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.